Recently, Yizhan Capital completed an exclusive investment of over RMB 50 million in Shanghai Boku Biotechnology Co., Ltd. ("Boku Bio" for short)
Boku Biotechnology is founded on the belief that high performance products and environmental responsibility can go hand in hand. Specializing in fermentation-derived natural ingredients, we are committed to replacing synthetic chemicals with sustainable alternatives for personal and home care, cosmetics, and industrial applications.
FOUNDER: Dr. Zhao Jie
· PhD of East China University of Science and Technology
· Led the completion of the industrialization of domestic nuclease from scratch
· Led the establishment of DSM (China) Biological R&D Center and DSM Colloid Global Biotechnology Center
· Completed the design, construction and operation of production lines for multiple microbial products
CO-FOUNDER: Dr. Huang Pinwei
· PhD from the University of Rochester, USA, postdoctoral fellow at MIT
· Nearly 20 years of experience in genetic engineering and protein engineering
· High-yield strain construction and industrialization of various enzyme products and functional molecules have been achieved
CO-FOUNDER: Dr. Ronnie Yuan
· PhD from Pennsylvania State University
· Former Chief Scientist of SPKK and Global Innovation Director of DSM Hydrocolloid
· Microbial colloid products developed are widely used in food, pharmaceutical and personal care products around the world
Bio-based surfactants are the company's current key industrialization area. Boku Bio uses naturally derived microbial strains to produce biosurfactants from renewable raw materials through a fermentation process, providing 100% bio-based surfactants for personal care, make-up, detergent industry to replace traditional chemical surfactants.
Boku Bio has built two R&D centers in Fengxian District, Shanghai and Tongxiang City, Zhejiang Province, and the cosmetic-grade biosurfactant manufacturing line has been put into production. At present, Boku Bio has successfully achieved the industrial scale-up and market supply of cosmetic-grade biosurfactants such as lactonic sophorolipids, acidic sophorolipids, rhamnolipids and sodium surfactin, and also supplies fermented oil products to leading companies in the personal care industry.
Yizhan Capital is committed to the core strategy of “industry as the foundation, capital as the wings,” dedicated to deeply integrating real industries with equity investment to build a unique “industry + capital” dual-drive model. Through industry cultivation and capital empowerment, it promotes scientific and technological innovation and industrial modernization, pursuing a path of high-quality development.
The additional investment in Boku Bio is not only an important step for Yizhan Capital to deepen its layout in the physical economy, but also a strategic milestone in its transformation and upgrading to a higher level. This investment will accelerate the company's in-depth development in the biotechnology and health industries, promote scientific and technological innovation and industrial chain upgrading. It marks Yizhan Capital's new height in the integration of industry and finance under the strategic guidance of “industry as the foundation, capital as the wings,” injecting strong momentum into the construction of a sustainable industrial ecosystem.
